Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps-Reference-Cited by-同舟云学术

Differentiation of pseudoprogression and real progression in glioblastoma using ADC parametric response maps

Published:2017-04-06 Issue:4 Volume:12 Page:e0174620
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Reimer Caroline,Deike Katerina,Graf Markus,Reimer Peter,Wiestler Benedikt,Floca Ralf Omar,Kickingereder Philipp,Schlemmer Heinz-Peter,Wick Wolfgang,Bendszus Martin,Radbruch Alexander

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference40 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;R Stupp;N Engl J Med,2005

2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial;R Stupp;Lancet Oncol,2009

3. Malignant gliomas in adults;PY Wen;N Engl J Med,2008

4. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group;PY Wen;J Clin Oncol,2010

5. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence;A Radbruch;Neuro Oncol,2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perioperative imaging predictors of tumor progression and pseudoprogression: A systematic review;Critical Reviews in Oncology/Hematology;2024-10

2. Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-06-13

3. Validation of daily 0.35 T diffusion‐weighted MRI for MRI‐guided glioblastoma radiotherapy;Medical Physics;2024-04-08

4. Differentiating tumour progression from pseudoprogression in glioblastoma patients: a monoexponential, biexponential, and stretched-exponential model-based DWI study;BMC Medical Imaging;2023-09-11

5. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses;Journal of Neuro-Oncology;2023-09